Cargando…

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomas

INTRODUCTION: Diffuse midline gliomas (DMG) are universally lethal central nervous system tumors that carry almost unanimously the clonal driver mutation histone-3 K27M (H3K27M). The single amino acid substitution of lysine to methionine harbors a neoantigen that is presented in tumor tissue. The lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grassl, Niklas, Sahm, Katharina, Süße, Heike, Poschke, Isabel, Bunse, Lukas, Bunse, Theresa, Boschert, Tamara, Mildenberger, Iris, Rupp, Anne-Kathleen, Ewinger, Max Philipp, Lanz, Lisa-Marie, Denk, Monika, Tabatabai, Ghazaleh, Ronellenfitsch, Michael W., Herrlinger, Ulrich, Glas, Martin, Krex, Dietmar, Vajkoczy, Peter, Wick, Antje, Harting, Inga, Sahm, Felix, von Deimling, Andreas, Bendszus, Martin, Wick, Wolfgang, Platten, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585906/ https://www.ncbi.nlm.nih.gov/pubmed/37853454 http://dx.doi.org/10.1186/s42466-023-00282-4

Ejemplares similares

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas
por: Bunse, Lukas, et al.
Publicado: (2022)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017)

Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)

T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells
por: Lu, Kevin Hai-Ning, et al.
Publicado: (2022)

Genetically Modified Cellular Therapies for Malignant Gliomas
por: Kilian, Michael, et al.
Publicado: (2021)

Comparative evaluation of T-cell receptors in experimental glioma-draining lymph nodes
por: Blobner, Jens, et al.
Publicado: (2021)

IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma
por: Kickingereder, Philipp, et al.
Publicado: (2015)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

In vivo nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental glioma
por: Hunger, Jessica, et al.
Publicado: (2023)

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
por: Friedrich, Mirco, et al.
Publicado: (2022)

Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
por: Ott, Martina, et al.
Publicado: (2012)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2015)

Does age matter? - A MRI study on peritumoral edema in newly diagnosed primary glioblastoma
por: Seidel, Clemens, et al.
Publicado: (2011)

T-cell Receptor Therapy Targeting Mutant Capicua Transcriptional Repressor in Experimental Gliomas
por: Kilian, Michael, et al.
Publicado: (2022)

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes
por: Kessler, Tobias, et al.
Publicado: (2020)

Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial
por: Kessler, Tobias, et al.
Publicado: (2023)

Intraventricular immune checkpoint inhibition with nivolumab in relapsed primary central nervous system lymphoma
por: Kaulen, Leon D, et al.
Publicado: (2022)

The Indoleamine-2,3-Dioxygenase (IDO) Inhibitor 1-Methyl-D-tryptophan Upregulates IDO1 in Human Cancer Cells
por: Opitz, Christiane A., et al.
Publicado: (2011)

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q – IMPROVE CODEL: the NOA-18 trial
por: Wick, A., et al.
Publicado: (2022)

Correlated MRI and Ultramicroscopy (MR-UM) of Brain Tumors Reveals Vast Heterogeneity of Tumor Infiltration and Neoangiogenesis in Preclinical Models and Human Disease
por: Breckwoldt, Michael O., et al.
Publicado: (2019)

AAMP is a binding partner of costimulatory human B7-H3
por: Ciprut, Sara, et al.
Publicado: (2022)

Clinical and Translational Advances in Glioma Immunotherapy
por: Bunse, Lukas, et al.
Publicado: (2022)

Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ
por: Kudo, Takumi, et al.
Publicado: (2020)

PATH-26. RNA SEQUENCING OF FORMALIN-FIXED PARAFFIN-EMBEDDED SPECIMENS IN DIAGNOSTIC ROUTINE IDENTIFIES CLINICALLY RELEVANT GENE FUSIONS
por: Stichel, Damian, et al.
Publicado: (2020)

Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
por: Litzenburger, Ulrike M., et al.
Publicado: (2014)

Intrathecal activation of CD8(+) memory T cells in IgG4‐related disease of the brain parenchyma
por: Friedrich, Mirco, et al.
Publicado: (2021)

Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
por: Elmadany, Nirmeen, et al.
Publicado: (2022)

The aryl hydrocarbon receptor in tumor immunity
por: Platten, Michael, et al.
Publicado: (2012)

Mutation specific antibodies: tool or dinosaur?
por: von Deimling, Andreas, et al.
Publicado: (2012)

Endothelial Indoleamine-2,3-Dioxygenase-1 is not Critically Involved in Regulating Antitumor Immunity in the Central Nervous System
por: Abu Hejleh, AP, et al.
Publicado: (2023)

Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis
por: Lanz, Tobias V., et al.
Publicado: (2017)

Single-Cell High-Throughput Technologies in Cerebrospinal Fluid Research and Diagnostics
por: Lanz, Tobias V., et al.
Publicado: (2019)

Loss of H3K27me3 in meningiomas: an independent marker for CNS WHO grade 2?
por: Behling, Felix, et al.
Publicado: (2023)

Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
por: Aslan, Katrin, et al.
Publicado: (2020)

Quantitative Susceptibility Mapping Differentiates between Blood Depositions and Calcifications in Patients with Glioblastoma
por: Deistung, Andreas, et al.
Publicado: (2013)

Automatic Analysis of Cellularity in Glioblastoma and Correlation with ADC Using Trajectory Analysis and Automatic Nuclei Counting
por: Eidel, Oliver, et al.
Publicado: (2016)

Tryptophan metabolism is inversely regulated in the tumor and blood of patients with glioblastoma
por: Panitz, Verena, et al.
Publicado: (2021)

Tumor cell plasticity, heterogeneity, and resistance in crucial microenvironmental niches in glioma
por: Jung, Erik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mt7t41tkgkgq4pvvgeh7s0paie